[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=de502d6e547d6c502d27f46c2f1d8e6e71f4463bec0e5e8993ef8c1b6cd618cc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733934840,
      "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "id": 131933391,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=de502d6e547d6c502d27f46c2f1d8e6e71f4463bec0e5e8993ef8c1b6cd618cc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Completes Acquisition of Aliada Therapeutics",
    "summary": "AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.",
    "url": "https://finnhub.io/api/news?id=57850508908d383de794ae31065ed2ec41f8d7a8f01454add41deeb6bb904d1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733926500,
      "headline": "AbbVie Completes Acquisition of Aliada Therapeutics",
      "id": 131933037,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.",
      "url": "https://finnhub.io/api/news?id=57850508908d383de794ae31065ed2ec41f8d7a8f01454add41deeb6bb904d1d"
    }
  },
  {
    "ts": null,
    "headline": "Betting Big On AbbVie: A Prescription For Growth And Dividends",
    "summary": "AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find out why ABBV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=149dfc296896d1b4f62c81a9149a70f3aec598513001a209d33a03d75ead49df",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733922724,
      "headline": "Betting Big On AbbVie: A Prescription For Growth And Dividends",
      "id": 131921184,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397335462/image_1397335462.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find out why ABBV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=149dfc296896d1b4f62c81a9149a70f3aec598513001a209d33a03d75ead49df"
    }
  },
  {
    "ts": null,
    "headline": "BenevolentAI restructures; Lilly preps $15B buyback program",
    "summary": "The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.",
    "url": "https://finnhub.io/api/news?id=80d1d039c420d9b837951d34429b37f0156acdd1ad7bd17e9fffb7159d683f48",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733913937,
      "headline": "BenevolentAI restructures; Lilly preps $15B buyback program",
      "id": 131923948,
      "image": "https://imgproxy.divecdn.com/EK5xKj0ydykvmwFmBqsauREtdhrHAUsAiyI6JgDkO1s/g:nowe:0:0/c:1207:682/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDgzOTIxNzkzLmpwZw==.webp",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The drug discovery specialist is laying off staff in a pivot that could take it private. Elsewhere, AbbVie reported a second Parkinson’s study success and Biogen hired a new Wall Street whisperer.",
      "url": "https://finnhub.io/api/news?id=80d1d039c420d9b837951d34429b37f0156acdd1ad7bd17e9fffb7159d683f48"
    }
  },
  {
    "ts": null,
    "headline": "Why Is AbbVie Inc. (ABBV) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?",
    "summary": "We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry are changing. […]",
    "url": "https://finnhub.io/api/news?id=74bec7a315c43301957ddc4140ab99c7e29793e2982e414a3778d46d925300ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733890625,
      "headline": "Why Is AbbVie Inc. (ABBV) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?",
      "id": 131912483,
      "image": "https://s.yimg.com/ny/api/res/1.2/m1YYSOl9HO_x0LHuYGlC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/c554ad8e2af773e2e2a8438bfe2291ee",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other cosmetic surgery and aesthetics stocks. In the face of economic uncertainty, consumer preferences in the beauty industry are changing. […]",
      "url": "https://finnhub.io/api/news?id=74bec7a315c43301957ddc4140ab99c7e29793e2982e414a3778d46d925300ee"
    }
  }
]